Jens Lagergren

Genomic characterization of ER-positive primary tumors and corresponding relapses identifies potentially targetable alterations

The majority of breast cancer patients have tumors expressing estrogen receptor α (ER) and receive endocrine therapy. However, around one-third relapse in their disease, predominantly with retained ER expression. Molecular alterations are proposed to be contributors to the resist...